Over the last seven decades, a significant scientific contribution took place in the delineation
of the implications of vascular endothelialderived growth factor (VEGF) in the processes of …

Ocular drug delivery has always been a challenge for ophthalmologists and drug-delivery
scientists due to the presence of various anatomic and physiologic barriers. Inimitable static …

The field of gene therapy is striving more than ever to define a path to the clinic and the
market. Twenty gene therapy products have already been approved and over two thousand …

Background: Age-related macular degeneration is a leading cause of severe, irreversible
vision impairment in developed countries. The primary risk factors for the development of …

Importance More than 1 billion people worldwide have vision impairment or blindness from
potentially preventable or correctable causes. Quality of life, an important measure of …

Background Agerelated macular degeneration (AMD) is the most common cause of
uncorrectable severe vision loss in people aged 55 years and older in the developed world …

This review summarizes the latest findings in the literature of Angiopoietin-2 (Ang-2),
Tyrosine-protein kinase receptor (Tie-2) complex, and faricimab along with their involvement …

Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is
controlled by the complicated and coordinated actions of pro-angiogenic factors and their …

Purpose Real-life clinical outcomes of patients treated with anti-VEGF drugs for neovascular
age-related macular degeneration (nAMD), diabetic macular edema (DME), or macular …

Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents is a
commonly used therapy for numerous retinal diseases. The most commonly used of these …